Although more studies are needed to demonstrate the ERα/β heterodimer as a therapeutic target, the concept of inducing ERβ to pair with ERα, thus antagonizing ERα's proliferative function, is distinct from existing breast cancer therapeutic strategies of targeting ERα alone. Here, ESR1 is linked to breast cancer.